May Sara R. 4

What Happened May Sara R., a director of Medicus Pharma Ltd. (MDCX), received an award/acquisition of 25,000 shares as a derivative grant on March 30, 2026. The filing shows an acquisition price of $0.00 (total reported value $0) and lists the transaction as code "A" (grant/award). This was an award/compensation-type transaction rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-30
• Transaction type/code: Award/Grant (A); classified as a derivative acquisition
• Price: $0.00 per share; total reported cash value $0
• Filing date: 2026-04-01 (filed timely under the Form 4 two-business-day rule)
• Shares owned after transaction: not specified in the excerpt provided
• Footnotes/plan references: none listed in the provided details (no 10b5-1, tax-withholding, or cashless-sale notes included)

Context Grants or awards to insiders are commonly compensation-related (e.g., restricted stock or RSUs) and do not necessarily indicate immediate buying or selling intent. Because this was a derivative award reported at $0, it likely reflects a compensation grant or award rather than a cash purchase; check the full Form 4 or company filings for vesting terms or related plan disclosures if you want details on when the shares become transferable.